• Corpus ID: 6715650

[Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].

@article{Barkhaleva2009VitaherpavacIT,
  title={[Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].},
  author={O. A. Barkhaleva and I P Ladyzhenskaia and M S Vorob'eva and N. V. Shalunova and R. I. Podcherniaeva and G. R. Mikhailova and Tatiana Khorosheva and I. F. Barinskiĭ},
  journal={Voprosy virusologii},
  year={2009},
  volume={54 5},
  pages={
          33-7
        }
}
Vitaherpavac, a dry inactivated herpes simplex virus (HSV) culture vaccine, has been obtained, by using the Vero B continuous cell line as a substrate for accumulation of herpes simplex virus types 1 (US strain) and 2 (VN strain). Vitaherpavac and the similar vaccine Herpovax made by the Research Institute of Vaccines and Sera, Saint Petersburg (for which preparation a primary trypsinized chick embryo cell culture used as a substrate for accumulation of HSV types 1 and 2), underwent comparative… 
1 Citations

The ongoing pursuit of a prophylactic HSV vaccine

  • E. ChungJ. Sen
  • Medicine, Political Science
    Reviews in medical virology
  • 2012
This time of year is a suitable time to assess the progress of HSV vaccine development and consider existing challenges and future improvements needed to achieve an effective prophylacticHSV vaccine.